In the global pharmaceutical landscape, regulatory approvals and compliance with national authorities play a pivotal role in ensuring drug safety, efficacy, and international acceptance. Understanding which regulatory bodies and standards apply in different countries is critical for manufacturers, exporters, and healthcare providers. Below is a comprehensive guide to recognized approvals and national regulatory authorities worldwide, categorized by country, along with associated global compliance frameworks such as PIC/S, WHO GMP, and EU GMP.


Argentina: ANMAT and INAME

Argentina’s pharmaceutical industry is regulated by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), which oversees drugs, foods, and medical devices. The National Institute of Medicines (INAME) is aligned with PIC/S standards, reinforcing international compliance.


Australia: TGA and WHO GMP

Australia adheres to PIC/S standards through the Therapeutic Goods Administration (TGA), which enforces Good Manufacturing Practices (GMP). Additionally, Australia recognizes WHO GMP certifications, ensuring global harmonization in pharmaceutical quality and safety.


Austria: AGES and EU GMP

Austria’s authority, the Austrian Agency for Health and Food Safety (AGES), regulates drug approvals under PIC/S. The country also enforces EU GMP requirements, aligning with European pharmaceutical standards.


Belgium: AFMPS and EU GMP

Belgium’s Federal Agency for Medicines and Health Products (AFMPS) plays a central role in drug regulation. As a PIC/S member, Belgium enforces EU GMP, ensuring high compliance levels for pharmaceutical manufacturers.


Brazil: ANVISA

Brazil’s ANVISA (Agência Nacional de Vigilância Sanitária) regulates pharmaceuticals and enforces national GMP standards while maintaining PIC/S alignment, which facilitates global trade and recognition.

Brazil GMP (ANVISA) – Complete Technical Details

1. Introduction to ANVISA and Brazil’s Regulatory Landscape

ANVISA (Agência Nacional de Vigilância Sanitária) is the national regulatory authority responsible for pharmaceutical oversight, GMP certification, product registration, clinical trials, pharmacovigilance, and sanitary control in Brazil.

Key characteristics:

  • Autonomous regulatory body linked to Brazil’s Ministry of Health
  • One of the most stringent GMP authorities in Latin America
  • Recognized for strong enforcement, detailed GMP inspections, and documentation-heavy requirements
  • Aligned with PIC/S (Pharmaceutical Inspection Co-operation Scheme) principles
  • Accepts certain harmonized procedures but retains its own Brazil-Specific GMP Regulations – RDC 301/2019

For Taj Pharma, understanding the granular technical details of Brazilian GMP is essential for successful product registration, contract manufacturing agreements, and export compliance.


2. Legal Framework Governing GMP in Brazil

Brazil’s GMP regulations are primarily governed by:

2.1 RDC 301/2019 (Primary GMP Regulation)

This is the Brazilian equivalent of EU GMP Part I & II, updated to align with PIC/S PE009.

RDC 301 covers:

  • Quality Management System (QMS)
  • Documentation & Records
  • Premises & Facilities
  • Equipment Qualification
  • Utilities (HVAC, Purified Water, WFI, Steam, Clean Compressed Air)
  • Production & In-Process Controls
  • QC Laboratory Guidelines
  • Validation Requirements
  • Contract Manufacturing & Outsourcing
  • Complaints, Recalls & Returns
  • Self-Inspection & Audits
  • Change Control & Risk Management

2.2 Other Supporting Regulations

  • RDC 304/2019 – Good Distribution & Storage Practices
  • RDC 39/2013 – Import licensing rules
  • RDC 47/2009 – APIs GMP guidelines
  • RDC 53/2015 – Post-registration variations
  • RDC 73/2016 – Stability studies requirements
  • RDC 73/2008 – Packaging material quality requirements

3. ANVISA GMP Certification (CBPF) – Step-by-Step Requirements

To export pharmaceuticals to Brazil, Taj Pharma would require:

3.1 CBPF Certificate (Certificado de Boas Práticas de Fabricação)

This is ANVISA’s official GMP certificate, mandatory before product registration.

Application Dossier Includes:

  1. DIFA/DMF or API Information
  2. CTD-format Site Master File (Modelo ANVISA)
  3. List of Products Intended for Brazil
  4. Layout Drawings (AutoCAD or PDF)
  5. Flowcharts of Material/Personnel Movement
  6. Water System Diagrams (URS, P&ID, Validation)
  7. HVAC Classification with Pressure Cascade
  8. Equipment List with Qualifications (IQ/OQ/PQ)
  9. Validation Master Plan (VMP)
  10. Cleaning Validation Matrix
  11. Process Validation Summary
  12. Analytical Method Validation Summaries
  13. Quality Risk Management Records (ICH Q9 alignment)
  14. Environmental Monitoring Program (EMP)
  15. Microbial Limits and Historical Trending
  16. Supplier Qualification System

4. ANVISA Inspection Process (Highly Stringent)

ANVISA inspectors are known for extreme detail orientation and often request:

4.1 Pre-inspection Document Review

  • All SOPs (500+ SOP list recommended)
  • Batch Manufacturing Records (BMRs) for commercial, validation & R&D lots
  • Batch Packaging Records (BPRs)
  • Stability ongoing data (zone IVB required)
  • Change control logs (last 3 years)
  • CAPA history and effectiveness checks
  • Pest control reports
  • HVAC reports with seasonal variation
  • Calibration & maintenance logs
  • Supplier audits

4.2 On-site inspection focus areas

Quality Management System

  • Data integrity compliance (ALCOA+)
  • Audit trails in QC systems
  • Training curriculum & competency evaluation
  • Product quality review (PQR) for last 2–3 years

Utilities Verification

  • HVAC system design, filtration, pressures, monitoring
  • Water system validation (PW/WFI) – Brazilian focus is strong on TOC, endotoxins
  • Clean compressed air qualification

Production & Documentation

  • Line clearance documentation
  • OOS/OOT handling
  • Raw material sampling SOPs
  • Batch numbering system

Quality Control Laboratory

  • Reagent traceability
  • Reference standard and working standard qualification
  • HPLC/GC calibration and audit trails
  • Microbiology testing, sterility validation, growth promotion tests

Warehouse & Storage

  • FEFO implementation
  • Temperature/humidity mapping
  • Cold chain validation (if applicable)

Inspection Result:

  • Compliant → CBPF issued (valid 2 years)
  • Deficiencies → CAPA required
  • Critical → Rejection or re-inspection

5. Brazil GMP vs EU GMP vs WHO GMP (Key Differences Important for Taj Pharma)

ParameterANVISA Brazil (RDC 301)EU GMPWHO GMP
Inspection StrictnessVery highHighModerate
StabilityMandatory Zone IVBIVB optionalIVB optional
Data IntegrityZero toleranceStrictModerate
Documentation in PortugueseRequired for certain submissionsNoNo
Cleaning ValidationProduct matrix mandatoryFlexibleFlexible
Packaging MaterialVery detailed under RDC 73/2008StandardStandard

Brazil emphasizes:

  • Cleaning validation rigor
  • Pharmaceutical water quality limits
  • Microbiological environmental monitoring
  • Very strict data integrity standards
  • Portuguese labeling requirement

6. ANVISA Expectations for Finished Dosage Form (FDF) Manufacturers

For Taj Pharma OSD formulations (tablets, capsules), ANVISA will expect:

6.1 Facility Design Requirements

  • Unidirectional flow of material and personnel
  • Segregation between dispensing, granulation, compression, coating, packing
  • Dedicated areas for APIs with high potency
  • Cross-contamination control strategy

6.2 Validation Requirements

  • Process Validation: Minimum 3 consecutive batches
  • Analytical Method Validation: Full ICH compliance
  • Cleaning Validation:
    • Worst-case product selection
    • MACO calculations in mg/cm²
    • Swab and rinse recovery factors

6.3 Stability Requirements

Brazil mandates Zone IVB (30°C / 75% RH) real-time data:

  • 0, 3, 6, 9, 12, 18, 24 months
  • Photostability (ICH Q1B)
  • Accelerated conditions (40°C / 75% RH)

6.4 Packaging and Labelling

  • Labels must be Portuguese Brazil
  • Mandatory ANVISA registration number
  • Traceability system (SNCM) compliance

7. Special Requirement: SNCM (Brazilian Serialization System)

Brazil has one of the most advanced serialization systems in the world.

Taj Pharma must comply with:

  • Unique Drug Identifier (UDI)
  • 2D Data Matrix Codes
  • Digital Transmission to ANVISA Portal
  • Serialization + Aggregation Requirements

8. Product Registration in Brazil (Post-GMP Approval)

Steps:

  1. Obtain CBPF GMP certificate
  2. Submit dossier in CTD format via ANVISA system
  3. Provide stability data for Brazil’s climatic zone
  4. Provide BE/Bioequivalence study reports for generics
  5. Provide pharmaceutical comparability data
  6. Provide batch analytical results from commercial-scale batches
  7. Label artwork submission in Portuguese

9. ANVISA Review Timelines (Realistic)

StageTimeline
GMP Application Review90–120 days*
On-Site Inspection3–12 months*
GMP Certificate Issuance30–60 days
Product Registration12–24 months

*Varies based on ANVISA backlog and priority categories.


10. Strategic Recommendations for Taj Pharma

To ensure smooth entry into the Brazilian market, Taj Pharma should:

10.1 Strengthen Documentation Systems

  • Ensure BMR/BPR error-free
  • Maintain complete audit trails
  • Purified water trending must be robust

10.2 Enhance Cleaning Validation Program

Brazil emphasizes cross-contamination risk more than many countries.

10.3 Stabilize Manufacturing Processes

Brazil requires very detailed process capability documentation.

10.4 Prepare for Portuguese Translation Needs

All labelling and some sections of dossier require translation.

10.5 Perform Internal Mock ANVISA Audit

Simulate a real ANVISA audit for:

  • HVAC
  • Water system
  • QC
  • Documentation
  • Validation

10.6 Ensure API Supplier Has Valid GMP

API suppliers also must meet Brazilian requirements.


Brazil’s GMP regime under ANVISA is one of the strictest globally, merging national laws with PIC/S harmonization. For Taj Pharma to succeed in Brazil:

  • Prepare for detailed inspections
  • Maintain data integrity discipline
  • Implement robust cleaning validation
  • Provide Zone IVB stability
  • Ensure Portuguese translations
  • Prepare all technical documentation in CTD format

With proper preparation, Taj Pharma can easily penetrate the Brazilian pharmaceutical market and maintain long-term regulatory compliance.


Bulgaria: Bulgarian Drug Agency

Bulgaria implements PIC/S standards, EU GMP guidelines, and oversight by the Bulgarian Drug Agency, strengthening pharmaceutical regulation within the European Union framework.


Canada: Health Canada and WHO GMP

Canada’s Health Canada ensures regulatory compliance under PIC/S membership, also recognizing WHO GMP certifications, strengthening its credibility in global pharmaceutical exports.


China (Taipei): TFDA

The Taiwan Food and Drug Administration (TFDA) under the Ministry of Health enforces PIC/S compliance, aligning with international GMP standards.


Croatia: HALMED

Croatia’s Agency for Medicinal Products and Medical Devices (HALMED) enforces PIC/S and EU GMP compliance, ensuring drug safety and quality assurance.


Cyprus: CyPHs

Cyprus regulates through Cyprus Pharmaceutical Services (CyPHs) under the Ministry of Health, adhering to PIC/S standards and EU GMP requirements.


Czech Republic: SUKL

The State Institute for Drug Control (SUKL) oversees pharmaceutical regulation in the Czech Republic. As a PIC/S member, the country enforces EU GMP standards across all manufacturing facilities.


Denmark: DKMA

The Danish Medicines Agency (DKMA) ensures compliance with PIC/S standards while operating under the umbrella of EU GMP regulations.


Estonia: SAM

The State Agency of Medicines (SAM) regulates pharmaceuticals in Estonia, enforcing PIC/S membership and EU GMP standards.


Finland: FIMEA

The Finnish Medicines Agency (FIMEA) operates under PIC/S compliance and enforces EU GMP frameworks for medicinal product safety.


France: ANSM

France’s National Agency for the Safety of Medicines and Health Products (ANSM) enforces strict pharmaceutical regulations, aligning with both PIC/S and EU GMP requirements.


Germany: BfArM

Germany regulates pharmaceuticals through the Federal Institute for Drugs and Medical Devices (BfArM), ensuring compliance with PIC/S standards and EU GMP certification.


Greece: EOM

Greece follows EU GMP standards and PIC/S frameworks, regulated by the National Organization for Medicines (EOM).


Hungary: National Institute of Pharmacy and Nutrition

Hungary enforces PIC/S and EU GMP compliance through its National Institute of Pharmacy and Nutrition.


Iceland: Icelandic Medicines Agency

Iceland ensures pharmaceutical compliance via the Icelandic Medicines Agency, adhering to PIC/S and EU GMP frameworks.


India: CDSCO

India’s Central Drugs Standard Control Organization (CDSCO) regulates the pharmaceutical sector, enforcing national GMP standards in line with WHO guidelines, ensuring global trade compatibility.

India GMP (CDSCO) – Extremely In-Depth Technical Details for Taj Pharma

1. Introduction to CDSCO and India’s Regulatory Ecosystem

CDSCO (Central Drugs Standard Control Organization) is India’s national authority responsible for:

  • GMP enforcement (Schedule M)
  • Pharmaceutical manufacturing licensing
  • Drug product approval & registration
  • Clinical trial regulation
  • Import/export regulatory control
  • Pharmacovigilance systems (PvPI)
  • Quality control laboratories oversight

CDSCO operates under the Ministry of Health & Family Welfare and functions through:

  • Headquarters (New Delhi)
  • Zonal, Sub-Zonal & Port Offices
  • Central Drug Laboratories (CDLs)
  • State FDA licensing authorities

For Taj Pharma, CDSCO GMP compliance is foundational for:

  • India market manufacturing
  • WHO/UN procurement programs
  • Global dossier acceptance (as CDSCO aligns with WHO GMP)
  • Export market approvals (GCC, Africa, Asia, CIS, LATAM)

2. Legal Framework Governing GMP in India

India’s pharmaceutical GMP standards derive primarily from:

2.1 Drugs and Cosmetics Act, 1940

Defines manufacturing requirements, penalties, product standards.

2.2 Drugs and Cosmetics Rules, 1945

Contains Schedule M – Good Manufacturing Practices, the core GMP framework.

2.3 Schedule M – Comprehensive GMP Structure

Covers:

  • Pharmaceutical factory premises
  • Equipment
  • Materials
  • Documentation
  • Production
  • QC
  • Validation
  • Personal hygiene
  • Sterile manufacturing
  • HVAC system
  • Water system
  • Packaging & labelling
  • Self-inspection
  • Contract manufacturing

CDSCO is progressively upgrading Schedule M to align more strongly with WHO GMP + PIC/S-equivalent systems, ensuring global harmonization.


3. CDSCO GMP Certification: Key Requirements for Manufacturers

Each manufacturing site (like Taj Pharma Sarigam OSD unit) must comply with CDSCO/state FDA inspection to obtain:

  • Manufacturing License (Form 25/28 for non-sterile; Form 28A for sterile)
  • GMP Certificate (Schedule M compliance)
  • COPP (Certificate of Pharmaceutical Product) for export under WHO format

3.1 Mandatory Documentation

CDSCO requires:

  1. Site Master File (WHO format)
  2. Validation Master Plan (VMP)
  3. HVAC qualification documents (DQ/IQ/OQ/PQ)
  4. Water system validation (PW/WFI)
  5. Stability studies Zone IVb
  6. List of SOPs for all QMS modules
  7. Equipment list with calibration & qualification
  8. Vendor qualification program
  9. Batch Manufacturing & Packaging Records
  10. Change control, deviation & CAPA logs
  11. Environmental Monitoring Programs

4. CDSCO GMP Quality Management System (QMS) Requirements

India’s GMP strongly focuses on:

4.1 Quality Policy & Quality Objectives

Should align with ICH Q10 principles.

4.2 Quality Assurance System

Includes:

  • Documentation control
  • Deviation management
  • Change control
  • CAPA
  • Batch release procedures
  • Internal audits

4.3 Product Quality Review (Annual)

Mandatory for each SKU, summarizing:

  • Yield variances
  • Deviations/OOS
  • Stability trends
  • Market complaints
  • Supplier performance

4.4 Quality Risk Management

CDSCO requires risk assessments per:

  • FMEA
  • HACCP
  • Fault-tree analysis

5. Facility & Equipment Requirements under CDSCO GMP

5.1 Premises and Plant Layout

CDSCO mandates:

  • Logical unidirectional flow of men/material
  • Segregation of critical areas
  • Dust control and containment
  • Dedicated areas for β-lactams, hormones, cytotoxics
  • Smooth, washable, non-permeable surfaces

5.2 HVAC Requirements

Key CDSCO expectations:

  • Pressure cascade definition
  • HEPA filters in critical zones
  • Periodic DOP/PAO testing
  • Adequate air changes per hour (ACH)
  • Temperature & humidity control

5.3 Water System Requirements

India follows WHO GMP standards:

  • Purified Water (PW) for oral solid dosage
  • Water for Injection (WFI) for sterile
  • Biofilm control
  • TOC and Conductivity trending
  • Sanitization frequency
  • PQ based on seasonal variation

5.4 Equipment Validation

All equipment must have:

  • URS
  • DQ / IQ / OQ / PQ
  • Preventive maintenance
  • Calibration program

6. Production & In-Process Control Requirements

CDSCO requires rigorous control over all production stages:

6.1 Raw Material Control

  • COA verification
  • Re-testing schedule
  • Sampling as per Indian Pharmacopoeia (IP) / ISO 2859

6.2 Granulation Controls (OSD)

  • Binder solution validation
  • Granule LOD requirement
  • Sieve integrity checks

6.3 Compression Controls

  • In-process sampling: weight, hardness, thickness
  • Compression machine controls: die punch wear, rejection monitoring

6.4 Coating Controls

  • Spray pattern, inlet/outlet temp, RH
  • Appearance and uniformity controls

6.5 Packaging Controls

  • Line clearance
  • Online IPCs
  • Countercheck reconciliation
  • Tamper-evident features

7. Quality Control Laboratory Requirements

QC labs must comply with:

7.1 Analytical Method Validation

Required for:

  • Assay
  • Related substances
  • Dissolution
  • Content uniformity

Following ICH Q2(R2).

7.2 Microbiology Testing

For non-steriles:

  • Total aerobic count
  • Yeast & mold
  • Pathogen absence test

For steriles:

  • Sterility testing
  • BET / LAL
  • Media fill validation

7.3 Stability Testing

CDSCO requires:

  • Zone IVb stability (30°C / 75% RH)
  • Accelerated studies (40°C / 75% RH)
  • Photostability (ICH Q1B)

8. Documentation Standards under Indian GMP

India is highly documentation-driven:

8.1 Good Documentation Practices (GDP)

  • No overwriting
  • Correct errors with reason and signature
  • Permanent ink only
  • Controlled document distribution
  • Proper issuance of logbooks

8.2 Types of Documents Required

  • SOPs
  • BMR/BPR
  • Protocols
  • Reports
  • QMS logs
  • Master validation plans
  • Preventive maintenance records

9. Validation Requirements

CDSCO mandates complete lifecycle validation:

9.1 Process Validation

  • Minimum 3 consecutive commercial-scale batches
  • Control strategy & CPPs/CMAs
  • Continued Process Verification (CPV) trending

9.2 Cleaning Validation

Key Indian focus:

  • MACO calculations
  • Shared equipment matrix
  • Swab/rinse recovery validation
  • Campaign-based manufacturing validation

9.3 Computerized System Validation (CSV)

Follows GAMP 5 guidelines:

  • Audit trails
  • Backup & recovery
  • User access control
  • Data integrity compliance (ALCOA+ principles)

10. Environmental & Microbiological Monitoring

CDSCO requires:

  • Grade D to Grade A classifications for sterile
  • Settle plates, swabs, and viable air sampling
  • Non-viable particulate count
  • Trending reports for 12 months

11. CDSCO Inspection Procedure for GMP Compliance

Inspections are conducted by:

  • State FDA inspectors
  • CDSCO Zonal offices
  • Joint CDSCO-state audits

11.1 Pre-Inspection Checklist

Inspectors review:

  • Site Master File
  • QMS documents
  • Validation data
  • HVAC & water system performance
  • BMRs of last 10–15 batches
  • Stability reports
  • Recall procedures
  • Market complaint handling

11.2 On-Site Inspection Focus Areas

Documentation Accuracy

Batch records and logbooks must be exact.

Data Integrity

ALCOA+ compliance:

  • Attributable
  • Legible
  • Contemporaneous
  • Original
  • Accurate

Production Practices

Inspectors observe:

  • Personnel hygiene
  • Material movement
  • Line clearance effectiveness
  • Sampling methods

QC Lab

  • Audit trails
  • Instrument calibration
  • Working standards qualification

11.3 Inspection Outcome

  • Compliant → GMP certificate / license renewal
  • Minor → CAPA submission
  • Major/Critical → Stop-production order, rejection, re-inspection

12. Export Certifications: WHO-COPP Requirements

For Taj Pharma’s exports, CDSCO issues:

  • COPP (Certificate of Pharmaceutical Product)
  • Based on WHO GMP inspection
  • Required by many markets (Africa, Asia, CIS, LATAM)

13. Upcoming Reforms Impacting Taj Pharma

India is modernizing GMP framework:

  • Complete alignment to PIC/S standard (future implementation)
  • Increased electronic documentation requirements
  • Stronger data integrity enforcement
  • Upgraded sterile guidelines (EU GMP Annex 1 alignment)

Taj Pharma should strategically prepare for these modernization changes.


14. Key Differences: Indian GMP vs WHO vs PIC/S

ParameterIndia (Schedule M)WHO GMPPIC/S
Legal statusMandatory lawGuidelineInternational standard
DocumentationVery detailedDetailedMost stringent
ValidationStrongStandardVery strong
Data IntegrityStrictModerateExtremely strict
InspectionsRegularLimitedVery deep audits

15. Strategic Recommendations for Taj Pharma

15.1 Strengthen QMS Digitization

  • LIMS
  • eBMR/eBPR
  • Electronic logbooks

15.2 Upgrade HVAC, Water & Automation

Essential for international exports.

15.3 Robust Validation Lifecycle

Maintain continuous trending.

15.4 Enhance Training & Competence

Inspector expectation: strong GMP knowledge at every level.

15.5 Mock CDSCO Audit

Internal audit team should conduct audits quarterly.


India’s CDSCO GMP framework is one of the world’s most detailed, combining statutory rules with WHO guidance. For Taj Pharma, achieving and maintaining full compliance ensures:

  • Smooth domestic licensing
  • International market acceptance
  • Strong quality reputation
  • Eligibility for UN/WHO procurement
  • Seamless regulatory submissions worldwide

Taj Pharma’s existing WHO-GMP, PIC/S-level compliance aligns well with CDSCO requirements, and strengthening internal systems will further enhance regulatory excellence.


Indonesia: BPOM

The National Agency for Drug and Food Control (BPOM) regulates pharmaceutical safety and efficacy in Indonesia.


Ireland: HPRA

Ireland operates under PIC/S and EU GMP compliance, regulated by the Health Products Regulatory Authority (HPRA).


Israel: Ministry of Health

Israel’s Ministry of Health ensures national pharmaceutical compliance with international standards.


Italy: Italian Medicines Agency

Italy’s pharmaceutical oversight is managed by the Italian Medicines Agency, which enforces PIC/S and EU GMP frameworks.


Japan: PMDA

Japan enforces pharmaceutical compliance through the Pharmaceuticals and Medical Devices Agency (PMDA). Japan is a PIC/S member and recognizes WHO GMP standards.


Kenya: Pharmacy and Poisons Board

Kenya regulates pharmaceuticals under its Pharmacy and Poisons Board, ensuring national compliance.


Latvia: State Agency of Medicines

Latvia enforces PIC/S and EU GMP requirements under the State Agency of Medicines.


Lithuania: State Medicines Control Agency

Lithuania’s State Medicines Control Agency operates under EU GMP and PIC/S frameworks.


Malaysia: NPRA

Malaysia enforces compliance through the National Pharmaceutical Regulatory Agency (NPRA), ensuring pharmaceutical quality and safety.


Malta: Medicines Authority

Malta regulates pharmaceuticals under EU GMP frameworks and PIC/S membership, managed by the Medicines Authority.


Mexico: COFEPRIS

Mexico’s COFEPRIS (Federal Commission for the Protection against Sanitary Risk) ensures compliance with PIC/S frameworks.


Netherlands: IGJ

The Health and Youth Care Inspectorate (IGJ) regulates pharmaceuticals in the Netherlands, enforcing EU GMP and PIC/S standards.


New Zealand: Medsafe

New Zealand’s Medsafe ensures pharmaceutical safety under PIC/S compliance and recognition of WHO GMP.


Nigeria: NAFDAC

Nigeria regulates pharmaceuticals under the National Agency for Food and Drug Administration and Control (NAFDAC).


Norway: NOMA

The Norwegian Medicines Agency (NOMA) ensures compliance with PIC/S standards and EU GMP certification.


Pakistan: DRAP

Pakistan’s Drug Regulatory Authority (DRAP) regulates pharmaceuticals nationally with WHO-aligned GMP.


Philippines: FDA

The Food and Drug Administration (FDA) in the Philippines regulates medicines, medical devices, and cosmetics under national compliance.


Poland: CPI

Poland enforces EU GMP compliance through the Chief Pharmaceutical Inspectorate (CPI), aligned with PIC/S standards.


Portugal: INFARMED

Portugal regulates pharmaceuticals under PIC/S and EU GMP frameworks, managed by INFARMED.


Romania: NAMMD

Romania enforces PIC/S compliance and EU GMP through the National Agency for Medicines and Medical Devices (NAMMD).


Russia: Ministry of Health

Russia regulates pharmaceuticals under the Ministry of Health of the Russian Federation, with national GMP standards.


Saudi Arabia: SFDA

Saudi Arabia’s Saudi Food and Drug Authority (SFDA) enforces compliance with PIC/S standards and national regulations.


Singapore: HSA

The Health Sciences Authority (HSA) in Singapore regulates under PIC/S frameworks, ensuring global credibility.


Slovakia: SUKL

Slovakia enforces EU GMP compliance through the State Institute for Drug Control, aligning with PIC/S standards.


Slovenia: JAZMP

Slovenia’s Agency for Medicinal Products and Medical Devices (JAZMP) regulates pharmaceuticals under EU GMP and PIC/S compliance.


South Africa: SAHPRA

The South African Health Products Regulatory Authority (SAHPRA) oversees pharmaceutical regulation with globally recognized standards.


Spain: AEMPS

Spain enforces EU GMP compliance under the Spanish Agency for Medicines and Health Products (AEMPS), aligned with PIC/S frameworks.


Sweden: MPA

Sweden’s Medical Products Agency (MPA) ensures compliance with EU GMP standards and PIC/S membership.


Switzerland: Swissmedic

The Swiss Agency for Therapeutic Products (Swissmedic) regulates pharmaceuticals under EU GMP and PIC/S frameworks.


Taiwan: TFDA

Taiwan enforces compliance through the Taiwan Food and Drug Administration (TFDA), aligned with PIC/S frameworks.


Thailand: Thai FDA

Thailand’s Food and Drug Administration operates under PIC/S compliance, ensuring international recognition.


Turkey: Turkish Medicines and Medical Devices Agency

Turkey enforces EU GMP and PIC/S frameworks, regulated nationally.


Ukraine: Ministry of Health

Ukraine regulates pharmaceuticals through its Ministry of Health, enforcing PIC/S compliance.


United Kingdom: MHRA

The Medicines and Healthcare Products Regulatory Agency (MHRA) oversees pharmaceutical regulation in the UK, enforcing EU GMP and PIC/S compliance.


United States: FDA

The U.S. Food and Drug Administration (FDA) is one of the most recognized global regulators, ensuring pharmaceutical compliance under strict national GMP standards.


Vietnam: Drug Administration of Vietnam

Vietnam regulates pharmaceuticals through the Drug Administration of Vietnam (DAV), ensuring alignment with WHO standards.


Navigating international pharmaceutical approvals requires a clear understanding of national regulatory authorities and global GMP frameworks such as PIC/S, EU GMP, and WHO GMP. Each country enforces its unique regulatory structure while aligning with global standards to ensure drug safety, efficacy, and international trade acceptance.